Literature DB >> 18829090

Biologic therapeutics and molecular profiling to optimize wound healing.

Marie N Menke1, Nathan B Menke, Cecelia H Boardman, Robert F Diegelmann.   

Abstract

Non-healing wounds represent a significant cause of morbidity and mortality for a large portion of the adult population. Wounds that fail to heal are entrapped in a self-sustaining cycle of chronic inflammation leading to the destruction of the extracellular matrix. Among cancer patients, malnutrition, radiation, physical dehabilitation, chemotherapy, and the malignancy itself increase the likelihood of chronic wound formation, and these co-morbidity factors inhibit the normal wound healing process. Current wound treatments are aimed at some, but not all, of the underlying causes responsible for delayed healing of wounds. These impediments block the normal processes that allow normal progression through the specific stages of wound healing. This review summarizes the current information regarding the management and treatment of complex wounds that fail to heal normally and offers some insights into novel future therapies [Menke N, Ward KR, Diegelmann R. Non-healing wounds. Emerg Med Rep 2007; 28(4).,Menke NB, Ward KR, Witten TM, Bonchev DG, Diegelmann RF. Impaired wound healing. Clin Dermatol 2007;25:19-25].

Entities:  

Mesh:

Year:  2008        PMID: 18829090      PMCID: PMC2592097          DOI: 10.1016/j.ygyno.2008.07.052

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  40 in total

Review 1.  Wound microbiology and associated approaches to wound management.

Authors:  P G Bowler; B I Duerden; D G Armstrong
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

Review 2.  ABC of arterial and venous disease. Ulcerated lower limb.

Authors:  N J London; R Donnelly
Journal:  BMJ       Date:  2000-06-10

Review 3.  The diabetic foot.

Authors:  Peter J Watkins
Journal:  BMJ       Date:  2003-05-03

Review 4.  Topical negative pressure devices: use for enhancement of healing chronic wounds.

Authors:  Miki Shirakawa; R Rivkah Isseroff
Journal:  Arch Dermatol       Date:  2005-11

Review 5.  Impaired wound healing.

Authors:  Nathan B Menke; Kevin R Ward; Tarynn M Witten; Danail G Bonchev; Robert F Diegelmann
Journal:  Clin Dermatol       Date:  2007 Jan-Feb       Impact factor: 3.541

Review 6.  Definitions and guidelines for assessment of wounds and evaluation of healing.

Authors:  G S Lazarus; D M Cooper; D R Knighton; D J Margolis; R E Pecoraro; G Rodeheaver; M C Robson
Journal:  Arch Dermatol       Date:  1994-04

Review 7.  Management of leg ulcers.

Authors:  P K Sarkar; S Ballantyne
Journal:  Postgrad Med J       Date:  2000-11       Impact factor: 2.401

8.  Vacuum-assisted closure for radiation-associated wound complications.

Authors:  Herrick J Siegel; James L Long; Kevin M Watson; John B Fiveash
Journal:  J Surg Oncol       Date:  2007-12-01       Impact factor: 3.454

9.  Tissue inhibitor of metalloproteinases-1 is decreased and activated gelatinases are increased in chronic wounds.

Authors:  E C Bullen; M T Longaker; D L Updike; R Benton; D Ladin; Z Hou; E W Howard
Journal:  J Invest Dermatol       Date:  1995-02       Impact factor: 8.551

10.  Fibronectin degradation in chronic wounds depends on the relative levels of elastase, alpha1-proteinase inhibitor, and alpha2-macroglobulin.

Authors:  F Grinnell; M Zhu
Journal:  J Invest Dermatol       Date:  1996-02       Impact factor: 8.551

View more
  11 in total

1.  The effect of porcine ADM to improve the burn wound healing.

Authors:  Xiaodong Chen; Yan Shi; Bin Shu; Xiaoxia Xie; Ronghua Yang; Lijun Zhang; Shubin Ruan; Yan Lin; Zepeng Lin; Rui Shen; Fenggang Zhang; Xiangsheng Feng; Julin Xie
Journal:  Int J Clin Exp Pathol       Date:  2013-10-15

2.  Maggot excretions/secretions induces human microvascular endothelial cell migration through AKT1.

Authors:  Shou-yu Wang; Kai Wang; Yi Xin; De-cheng Lv
Journal:  Mol Biol Rep       Date:  2009-09-16       Impact factor: 2.316

3.  Angiotensin and systems thinking: wrapping your mind around the big picture.

Authors:  Gary Robert Smith
Journal:  Ochsner J       Date:  2013

4.  Effect of low-level laser therapy on angiogenesis and matrix metalloproteinase-2 immunoexpression in wound repair.

Authors:  Melyssa Lima de Medeiros; Irami Araújo-Filho; Efigênia Maria Nogueira da Silva; Wennye Scarlat de Sousa Queiroz; Ciro Dantas Soares; Maria Goretti Freire de Carvalho; Maria Aparecida Medeiros Maciel
Journal:  Lasers Med Sci       Date:  2016-09-20       Impact factor: 3.161

5.  MicroRNA-222 regulates the viability of fibroblasts in hypertrophic scars via matrix metalloproteinase 1.

Authors:  Yi Zhang; Xiaohua Lin; Li Zhang; Weilong Hong; Kang Zeng
Journal:  Exp Ther Med       Date:  2017-12-14       Impact factor: 2.447

6.  Treatment of human chronic wounds with autologous extracellular matrix/stromal vascular fraction gel: A STROBE-compliant study.

Authors:  Chengliang Deng; Liangyue Wang; Jingwei Feng; Feng Lu
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.889

7.  MicroRNA-663 regulates the proliferation of fibroblasts in hypertrophic scars via transforming growth factor-β1.

Authors:  Qi Chen; Tianlan Zhao; Xiaoming Xie; Daojiang Yu; Lijun Wu; Wenyuan Yu; Wei Sun
Journal:  Exp Ther Med       Date:  2018-06-22       Impact factor: 2.447

8.  Cell density-dependent proteolysis by HtrA1 induces translocation of zyxin to the nucleus and increased cell survival.

Authors:  Fabio Sabino; Elizabeta Madzharova; Ulrich Auf dem Keller
Journal:  Cell Death Dis       Date:  2020-08-21       Impact factor: 8.469

Review 9.  Selective toxicity of antibacterial agents-still a valid concept or do we miss chances and ignore risks?

Authors:  Axel Dalhoff
Journal:  Infection       Date:  2020-12-23       Impact factor: 7.455

Review 10.  The Role of Matrix Metalloproteinases in Diabetic Wound Healing in relation to Photobiomodulation.

Authors:  Sandra Matabi Ayuk; Heidi Abrahamse; Nicolette Nadene Houreld
Journal:  J Diabetes Res       Date:  2016-05-23       Impact factor: 4.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.